Shilpa Medicare has received final USFDA approval for Docetaxel Injection, used for treatment of various types of cancers. The company will market the inaction in strengths of 20 mg/mL, 80 mg/4 mL (20 mg/mL), and 160 mg/8 mL (20 mg/mL).
The product Docetaxel Injection USP is a generic equivalent of reference listed drug (RLD) Taxotere used in the treatment of breast cancer, non-small cell lung cancer, prostate cancer, castric adenocarcinoma, head and neck cancer as recommended in the label approved by USFDA. According to market estimates, the US market for Docetaxel Injection USP is approximately USD 32.13 million.
Company Profile : Shilpa Medicare Ltd